Biomarker: K075-IgE Isocyanate TDI

Overview

K075-IgE Isocyanate TDI measures serum immunoglobulin E (IgE) antibodies that recognize toluene diisocyanate (TDI), usually presented in the assay as a TDI-protein conjugate. TDI is a low-molecular-weight respiratory sensitizer associated with occupational asthma and other airway effects. A detectable or elevated result indicates immunologic sensitization to the tested TDI antigen, but a negative result does not exclude TDI-related occupational asthma because many affected individuals do not have detectable specific IgE. The test is most useful as an adjunct to an occupational history, lung-function testing, serial peak-flow measurements, and, when clinically indicated, supervised bronchial challenge testing.

Clinical Use Cases

Supporting evaluation of suspected TDI-induced occupational asthma.
Identifying TDI sensitization in workers with work-related wheezing, cough, chest tightness, or shortness of breath.
Helping distinguish TDI from other occupational isocyanates as a potential sensitizing agent.
Supporting occupational and respiratory research involving immune responses to TDI exposure.
Monitoring specific IgE in longitudinal occupational assessments, recognizing that levels may decline after exposure ends.

Specimen Types

Serum, obtained from venous blood.
Plasma may be accepted by some specific-IgE immunoassay platforms, but specimen requirements are method-dependent.

Measurement Methods

Fluorescence enzyme immunoassay using an immobilized TDI-protein conjugate.
Radioallergosorbent testing, including older RAST or Phadebas RAST methods.
Enzyme-linked immunosorbent assay using TDI-human serum albumin conjugates.
Other validated allergen-specific IgE immunoassays, including chemiluminescent platforms.

Test Preparation and Influencing Factors

Fasting is generally not required for an allergy blood test.
Report all medications and supplements to the healthcare professional. Antihistamines usually do not interfere with serum specific-IgE testing in the same way they can affect skin testing, but medication changes should only be made under clinical direction.
Collection soon after the most recent occupational exposure may improve detection. In one clinical study, sensitivity was highest when blood was collected within 30 days of the last exposure.
Specific IgE concentrations may decrease during periods away from TDI exposure, which can contribute to a negative result in previously exposed workers.
Assay results depend on the TDI-protein conjugate used. Different conjugates may detect different antibody populations and may produce different sensitivities.
High total IgE or nonspecific binding can affect interpretation. Total IgE and appropriate assay controls may be useful when evaluating an isocyanate-specific result.
A positive result indicates sensitization to the tested antigen and does not, by itself, establish that workplace exposure caused asthma or predict the severity of a clinical reaction.
A negative result does not exclude TDI-induced asthma because TDI-related disease can involve mechanisms other than detectable specific IgE.